En omhyggelig risiko/ benefit evaluering, incl. neurologisk vurderinig, anbefales når Enbrel udskrives til patienter med eksisterende eller begyndende CNS demyeliniserings sygdomme, eller til patienter som vurderes at have en øget risiko for at udvikle demyeliniseringssygdom.
A careful risk/ benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel to patients with pre-existing or recent onset of CNS demyelinating disease, or to those who are considered to have an increased risk of developing demyelinating disease.